Icosabutate: targeting metabolic and inflammatory pathways for the treatment of NASH.

Fraser DA, Harrison SA, Schuppan D. Expert Opin Investig Drugs. 2022 Dec;31(12):1269-1278. doi: 10.1080/13543784.2022.2159804.

in cat NOT

Stay Connected

Would you like to receive updates from ProSciento?

Metabolic Continuum Roundtable
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.